Developing Therapeutics Targeting ICE Regulators
A heatmap of changes in cell behaviour following environmental change.
Image taken from Killaars et al., 2018, Adv.Sci.2019, 6, 1801483
MicroQuin focuses in-house efforts on Cancer, while progressing Anti-Virals and Neuro with the support of collaborators.
Lead Program
- Oncology
All Cancers induce an extreme ICE, which hyperactivates ICE regulators to neutralize ICE change, and promote cancer survival. MicroQuin’s therapeutics selectively inhibit cancer ICE regulators to induce death.
MicroQuin’s lead compound selectively binds cancerous cells in vivo to induce rapid tumor cell death (>95% in 28 day). No toxicity or adverse effects were measured.
Treatment of breast cancer tumor with placebo (untreated), standard of care (Tamoxifen), or MicroQuin's therapeutics (MQ treatment).
Anti-Viral
support by NIAID
Viruses hijacks the host cell to establish an ICE that enables them to replicate and spread. MicroQuin’s therapeutics activate ICE regulators, neutralizing viral-induced ICE changes, resulting in full viral inhibition.
MicroQuin’s anti-virals induce >99.9% viral inhibition from a single dose, thereby stopping viral replication and spread.
Neuro
Neurodegenerative disease is a ‘catch all term’ for a complex process of ICE changes that result in neurological damage. In the case of TBI, all secondary injury is caused by ICE change, enabling injury progression.
MQ Therapeutics can reverse secondary brain injury / ICE change, transforming damaged neurons into uninjured neurons
